In clinical trials, donanemab (Kisunla) modestly slowed the pace of thinking declines among patients in the early stages of the memory-robbing disease. But it also carried significant safety risks, including...
Vigorous physical activity may preserve cognitive function in high-risk HTN
Jun 24, 2024
High versus low vigorous physical activity was linked to a lower risk of mild cognitive impairment, probable dementia and MCI/probable dementia in a multivariate model.
Cognitive impairment delayed with genetic variant
Jun 20, 2024
The onset of cognitive impairment was delayed among those heterozygous for the apolipoprotein E3 Christchurch variant.
Lifestyle intervention can improve cognition, function in early Alzheimer’s disease
Jun 13, 2024
A significant correlation was seen between lifestyle and both cognitive function and Aβ42/40 ratio.
The 5-Cog paradigm improves diagnosis, management of dementia
Jun 11, 2024
A threefold improvement was seen in dementia care actions with the 5-Cog paradigm, a culturally adept cognitive detection tool.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Study identifies factors that predict driving cessation in seniors
May 22, 2024
Older age, female sex and progression to symptomatic Alzheimer’s disease were associated with driving cessation.
Benefit of thick liquids in Alzheimer’s disease and dysphagia unclear
May 06, 2024
Patients receiving thick versus thin liquids were less likely to be intubated and more likely to have respiratory complications.
Distance to neurologist, PCP may explain Alzheimer’s disease disparities
Apr 05, 2024
Non-Hispanic American Indian and/or Alaska Native and Hispanic decedents have to travel further to neurologist than non-Hispanic whites.
Higher education may protect functioning with Alzheimer’s disease
Apr 03, 2024
The findings were seen among African American individuals, with greater protective effect in APOE ɛ4 noncarriers.